HMGB1 and Miyoshi myopathy: Because of the crucial roles mentioned in Section 2, HMGB1 is becoming a potentially actionable target in molecular oncology for MM, with some recent preclinical evidence that suggests novel therapeutic approaches targeting HMGB1 in human MM, as listed in Table 1.